



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

January 26, 2024

Zhengbin (Bing) Yao, Ph.D.  
Chief Executive Officer  
ArriVent Biopharma, Inc.  
18 Campus Boulevard, Suite 100  
Newtown Square, PA 19073

**Re: ArriVent Biopharma, Inc.  
Registration Statement on Form S-1  
Exhibit Nos. 10.12, 10.13, 10.14 and 10.15  
Filed January 5, 2024  
File No. 333-276397**

Dear Zhengbin (Bing) Yao:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences